Poner atención a la diversidad de voces es fundamental a medida que continuamos con nuestra meta de escuchar, aprender y actuar contra el racismo y la discriminación.
Hearing from diverse voices is critical as we continue our journey to listen, learn, and take action against racism and discrimination.
The CF Foundation has successfully completed a sale of its remaining stake in royalties related to Vertex's CFTR modulators for an upfront payment of $575 million and a potential future payment of $75 million, bringing additional resources to the fight against CF.
On Aug. 27, leaders from the Cystic Fibrosis Foundation, along with several people from the CF community, participated in a virtual public meeting hosted by the Institute for Clinical and Economic Review to provide insights and expertise on the value of CFTR modulators.
Thirty-three new projects are being funded as part of the Foundation's $100 million Infection Research Initiative.
Recipients include four programs from around the country that engage and empower the CF community.
The Cystic Fibrosis Foundation awarded nearly $700,000 to Calibr, the drug discovery and development arm of Scripps Research, to screen for a compound that could be used to treat Burkholderia cepacia complex infections.